BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Financial Statements and Exhibits
Press release of Bristol-Myers Squibb Company dated December 19, 2018.
BRISTOL MYERS SQUIBB CO Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical Holdings Co.,…
To view the full exhibit click
About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.